Cybin (NASDAQ:HELP) Announces Earnings Results

Cybin (NASDAQ:HELP) issued its quarterly earnings data on Monday. The company reported $999.00 earnings per share (EPS) for the quarter, Zacks reports.

Cybin Trading Up 4.0%

HELP opened at $6.74 on Monday. Cybin has a 12 month low of $3.76 and a 12 month high of $9.83. The stock has a market capitalization of $348.10 million, a price-to-earnings ratio of -1.62 and a beta of 0.74. The stock has a 50-day moving average of $4.86.

Analyst Ratings Changes

Several analysts have issued reports on the stock. TD Cowen assumed coverage on shares of Cybin in a research report on Monday, April 13th. They set a “buy” rating for the company. HC Wainwright upped their price objective on Cybin from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $58.75.

Institutional Investors Weigh In On Cybin

Several large investors have recently modified their holdings of HELP. Osaic Holdings Inc. raised its holdings in shares of Cybin by 46.7% in the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock worth $63,000 after buying an additional 2,400 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Cybin by 66.8% in the second quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after acquiring an additional 11,790 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of Cybin by 1,388.5% during the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after purchasing an additional 959,448 shares during the last quarter. Institutional investors own 17.94% of the company’s stock.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.